[go: up one dir, main page]

BR9811521A - Composição para tratar ou impedir a glomerulopatia - Google Patents

Composição para tratar ou impedir a glomerulopatia

Info

Publication number
BR9811521A
BR9811521A BR9811521-9A BR9811521A BR9811521A BR 9811521 A BR9811521 A BR 9811521A BR 9811521 A BR9811521 A BR 9811521A BR 9811521 A BR9811521 A BR 9811521A
Authority
BR
Brazil
Prior art keywords
composition
glomerulopathy
treat
optionally substituted
prevent
Prior art date
Application number
BR9811521-9A
Other languages
English (en)
Inventor
Hidetake Kurihara
Fumihiko Watanabe
Yoshinori Tamura
Toshihiro Sinosaki
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR9811521A publication Critical patent/BR9811521A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/22—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms
    • C07C311/29—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound oxygen atoms having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/45—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the singly-bound nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfonamides
    • C07C311/46—Y being a hydrogen or a carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/18—Radicals substituted by singly bound hetero atoms other than halogen by sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Patente de Invenção: <B>"COMPOSIçãO PARA TRATAR OU IMPEDIR A GLOMERULOPATIA"<D>. Uma composição para tratar ou impedir a glomerulopatia que contém um composto da fórmula (I): em que, por exemplo, R^ 1^ e R^ 2^ são cada um independentemente átomos de hidrogênio, alquila inferior substituída opcionalmente, aralquila substituída opcionalmente, etc, R^ 3^ é 1,4-fenileno e 2,5-tiofendiila, R^ 4^ é um dos substituintes representados pela fórmula, etc.: em que R^ 6^ é um átomo de hidrogênio, amino substituído opcionalmente, etc.; e Y é NHOH ou OH, sua substância ativa oticamente, seus sais aceitáveis farmaceuticamente ou hidratos dos mesmos.
BR9811521-9A 1997-07-22 1998-07-17 Composição para tratar ou impedir a glomerulopatia BR9811521A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP19541497 1997-07-22
PCT/JP1998/003226 WO1999004780A1 (fr) 1997-07-22 1998-07-17 Agent therapeutique ou prophylactique de traitement de la glomerulopathie

Publications (1)

Publication Number Publication Date
BR9811521A true BR9811521A (pt) 2000-08-22

Family

ID=16340702

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9811521-9A BR9811521A (pt) 1997-07-22 1998-07-17 Composição para tratar ou impedir a glomerulopatia

Country Status (21)

Country Link
US (2) US6423729B1 (pt)
EP (2) EP1398027B1 (pt)
JP (1) JP3621427B2 (pt)
KR (1) KR100386148B1 (pt)
CN (1) CN1198607C (pt)
AT (1) ATE320801T1 (pt)
AU (1) AU737218B2 (pt)
BR (1) BR9811521A (pt)
CA (1) CA2297011C (pt)
DE (2) DE69836877D1 (pt)
HU (1) HUP0003851A3 (pt)
ID (2) ID24105A (pt)
IL (1) IL133933A0 (pt)
NO (1) NO20000285L (pt)
NZ (1) NZ502274A (pt)
PL (1) PL338235A1 (pt)
RU (1) RU2207849C2 (pt)
SK (1) SK262000A3 (pt)
TR (2) TR200100389T2 (pt)
TW (2) TW593249B (pt)
WO (1) WO1999004780A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69836877D1 (de) * 1997-07-22 2007-02-22 Shionogi & Co Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie
US6410580B1 (en) 1998-02-04 2002-06-25 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
IL137465A0 (en) 1998-02-04 2001-07-24 Novartis Ag Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases
AU5647099A (en) * 1998-09-11 2000-04-03 Shionogi & Co., Ltd. Remedal or preventive agent for congestive heart failure
KR20010113820A (ko) * 1999-04-19 2001-12-28 시오노 요시히코 옥사디아졸 고리를 갖는 술폰아미드 유도체
FR2798589B1 (fr) * 1999-09-16 2001-11-30 Oreal Composition cosmetique comprenant au moins un copolymere silicone/acrylate et au moins un agent epaississant
US6727266B2 (en) 2000-01-26 2004-04-27 Shionogi & Co., Ltd. Substituted tryptophan derivatives
WO2001070675A2 (en) * 2000-03-24 2001-09-27 Methylgene, Inc. Inhibitors of histone deacetylase
RU2275371C2 (ru) * 2000-04-21 2006-04-27 Шионоги Энд Ко., Лтд. Производные оксадиазола, обладающие противоопухолевым действием, лекарственное средство, их содержащее, и способ лечения
WO2001083464A1 (fr) * 2000-04-21 2001-11-08 Shionogi & Co., Ltd. Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire
US6897237B2 (en) 2000-04-28 2005-05-24 Shionogi & Co. Ltd. MMP-12 inhibitors
WO2001083461A1 (fr) * 2000-04-28 2001-11-08 Shionogi & Co., Ltd. Derives de thiazole et d'oxazole
JPWO2002028844A1 (ja) * 2000-09-29 2004-02-12 塩野義製薬株式会社 チアゾールおよびオキサゾール誘導体
MXPA04003451A (es) 2001-10-09 2005-02-17 Dimensional Pharm Inc Difeniloxazoles substituidos, la sintesis de los mismos y el uso de los mismo como detectores fluorescencia.
EP1461313B1 (en) * 2001-12-14 2009-08-05 Exelixis, Inc. Human adam-10 inhibitors
HRP20041138A2 (en) 2002-05-29 2005-04-30 Merck & Co. Inc. Compounds useful in the treatment of anthrax and inhibiting lethal factor
US7825146B2 (en) 2003-07-30 2010-11-02 Shionogi & Co., Ltd. Sulfonamide derivative having isoxazole ring
US7504431B2 (en) * 2004-04-16 2009-03-17 Bristol-Myers Squibb Company Sulfonyl amide inhibitors of calcium channel function
AU2005250351A1 (en) 2004-05-11 2005-12-15 Merck & Co., Inc. Process for making n-sulfonated-amino acid derivatives
JP2006036691A (ja) * 2004-07-27 2006-02-09 Shionogi & Co Ltd 腎炎の治療または予防剤
US20080119513A1 (en) * 2004-09-06 2008-05-22 Fumihiko Watanabe Sulfonamide Derivative Selectively Inhibiting Mmp-13
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
US20090069304A1 (en) 2006-03-03 2009-03-12 Shionogi & Co., Ltd. Mmp-13 selective inhibitor
EP2128134A1 (en) 2006-11-02 2009-12-02 Shionogi&Co., Ltd. Sulfonylurea derivative capable of selectively inhibiting mmp-13
CN102325768B (zh) * 2008-12-23 2016-11-09 阿奎卢斯制药公司 治疗疼痛和其他疾病的化合物和方法
CN110997651B (zh) 2017-08-17 2023-01-03 葛兰素史密斯克莱知识产权发展有限公司 新的四唑化合物和它们在治疗结核病中的用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03204875A (ja) * 1989-10-03 1991-09-06 Wakamoto Pharmaceut Co Ltd テトラゾール酢酸誘導体、及び該誘導体を有効成分とするアルドースレダクターゼ阻害剤
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
JP3818322B2 (ja) * 1994-04-28 2006-09-06 敏一 中村 コラーゲン分解促進剤
JPH10507158A (ja) 1994-06-22 1998-07-14 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤
KR980009238A (ko) * 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
BR9609883A (pt) 1995-08-08 1999-03-23 Fibrogen Inc Composto tendo efeito inibidor em proteinase c composição farmacéutica e processo para tratar doenças relacionadas com a produção inapropriada ou desregulada de colágeno
ATE226936T1 (de) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
JPH09110864A (ja) * 1995-08-10 1997-04-28 Kureha Chem Ind Co Ltd クロモン誘導体、その製造方法及び医薬組成物
JPH0987178A (ja) 1995-09-22 1997-03-31 Toyama Chem Co Ltd 神経成長因子の作用増強剤
JPH0987176A (ja) 1995-09-26 1997-03-31 Shiseido Co Ltd 糸球体腎炎抑制剤
ATE359264T1 (de) 1996-01-23 2007-05-15 Shionogi & Co Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten
CA2242416C (en) * 1996-01-23 2006-03-21 Shionogi & Co., Ltd. Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same
PL186416B1 (pl) 1996-05-17 2004-01-30 Warner Lambert Co Związek bifenylosulfonamidowy i preparat farmaceutyczny zawierający ten związek
WO1997045402A1 (fr) * 1996-05-24 1997-12-04 Ono Pharmaceutical Co., Ltd. Derives de phenylsulfonamide
KR20000067964A (ko) 1996-07-22 2000-11-25 죤 에이치. 뷰센 티올 술폰아미드 메탈로프로테아제 저해제
KR20010005940A (ko) * 1997-04-01 2001-01-15 아구론 파마슈티컬스, 인크. 메탈로프로테이나제 억제제를 포함하는 약제학적 조성물 및 이의 약제학적 용도
DE69836877D1 (de) * 1997-07-22 2007-02-22 Shionogi & Co Verwendung von Matrix- Metalloproteinase Inhibitoren zur Behandlung oder Vorbeugung von Glomerulopathie

Also Published As

Publication number Publication date
SK262000A3 (en) 2001-01-18
CN1198607C (zh) 2005-04-27
DE69833940T2 (de) 2006-12-14
ATE320801T1 (de) 2006-04-15
ID24105A (id) 2000-07-06
US20030078434A1 (en) 2003-04-24
KR20010022106A (ko) 2001-03-15
RU2207849C2 (ru) 2003-07-10
TW200400934A (en) 2004-01-16
DE69836877D1 (de) 2007-02-22
ID29293A (id) 1999-01-28
TR200100389T2 (tr) 2001-08-21
EP1029541A4 (en) 2000-08-23
US6423729B1 (en) 2002-07-23
JP3621427B2 (ja) 2005-02-16
HUP0003851A3 (en) 2002-10-28
IL133933A0 (en) 2001-04-30
TWI249518B (en) 2006-02-21
US6878739B2 (en) 2005-04-12
EP1029541B1 (en) 2006-03-22
CA2297011C (en) 2007-01-30
AU8243998A (en) 1999-02-16
DE69833940D1 (de) 2006-05-11
CN1270518A (zh) 2000-10-18
TR200000214T2 (tr) 2000-09-21
PL338235A1 (en) 2000-10-09
AU737218B2 (en) 2001-08-09
NO20000285L (no) 2000-03-22
WO1999004780A1 (fr) 1999-02-04
NO20000285D0 (no) 2000-01-20
TW593249B (en) 2004-06-21
EP1398027B1 (en) 2007-01-10
EP1398027A1 (en) 2004-03-17
NZ502274A (en) 2001-03-30
HUP0003851A2 (hu) 2001-07-30
EP1029541A1 (en) 2000-08-23
CA2297011A1 (en) 1999-02-04
KR100386148B1 (ko) 2003-06-02

Similar Documents

Publication Publication Date Title
BR9811521A (pt) Composição para tratar ou impedir a glomerulopatia
BR9913592A (pt) Compostos, processo de preparação dos compostos, e, composições farmacêuticas
NO308736B1 (no) 1,2-difenylpyrrolderivater, farmasøytiske preparater inneholdende disse, og deres anvendelse
BR9712959B1 (pt) nitratos orgánicos anti-trombóticos de inibidores da ace.
BR9803883A (pt) Derivado de amida.
MY133473A (en) Haterocyclic glycyl beta-alanine derivatives.
BR9807339A (pt) Derivados 3-piperidil-4-oxoquinazolina e composições farmacêuticas compreendendo os mesmos.
ATE269312T1 (de) N-(amidinophenyl)-n&#39;-(subst.)-3h-2,4- benzodiazepin-3-on derivative als faktor xa inhibitoren
TW200420542A (en) A compound having TGF β inhibition activity and a medicinal composition containing the same
NO20001045L (no) Nye cycliske tetrapeptidderivater og medisinsk anvendelse derav
MY113733A (en) Salts of an anti-migraine indole derivative
BR9813390A (pt) Composto, processo para a preparação do mesmo, e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, processo para efetuar a imunossupressão
NO953844L (no) 1-amidinofenyl-pyrrolidoner piperidinoner azetinoner som plateaggregeringshemmere
KR920008024A (ko) 퀴놀린 유도체
DK0564350T3 (da) 3, 5-di-tert-butyl-4-hydroxyflavoner, fremgangsmåde til deres fremstilling og farmaceutiske sammensætninger med antioxidant- og anti-vasokonstriktorisk virkning
BR9809062A (pt) Inibidores da metaloproteinase, composições farmacêuticas comtendo os mesmos e seus usos farmacêuticos
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
BR9814376A (pt) Composto ou um pró-medicamento correspondente, ou um sal farmaceuticamente aceitável ou solvato de um tal composto ou um pró-medicamento deste, uso destes, composição farmacêutica, processo para o tratamento de um paciente humano ou animal não humano sofrendo de, ou sujeito a, condições que podem ser melhoradas pela admnistração de um inibidor da adesão celular mediada por &amp;4ß1, e, resina
BR0014615A (pt) Derivado de ácido fosfÈnico que apresenta atividade inibidora contra carboxipeptidase b
BR9910206A (pt) Derivados de higromicina a.
NO20003106L (no) Akronycin-forbindelser, fremstilling derav samt farmasøytiske sammensetninger omfattende slike
BR9813775A (pt) Uso de um composto, processo para o tratamento de uma condição de cefaléia vascular, e, composição farmacêutica adequada para uso no tratamento de uma condição de cefaléia vascular.
BR0002516A (pt) Compostos úteis em terapia
BR0002075A (pt) Compostos 2,3-metano-aminoácidos, um processo para sua preparação e composições farmacêuticas que os contêm
BR9907426A (pt) Tetrahidronaftalenos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.8: C07D 333/18, C07D 413/04, C07D 271/06, A61K 31/381, A61K 31/422, A61K 31/4225, A61P 13/12

Ipc: C07D 333/18 (2007.01), C07D 413/04 (2007.01), C07D

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements